The world’s largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said on Tuesday.
But a continued surge could result in more delays because the Serum Institute of India would have to meet domestic needs, Adar Poonawalla warned in an interview with The Associated Press.
For more coronavirus news, visit our dedicated page.
The company is a key supplier for the UN-backed COVAX program that aims to distribute vaccines equitably in the world.
On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses.
For all the latest headlines follow our Google News channel online or via the app.
Since then, daily new infections in India have almost doubled, with the biggest single-day spike of over 100,000 new cases on Monday. Infections are being reported faster in India than anywhere else in the world, prompting tougher virus restrictions in New Delhi and its financial capital, Mumbai.
India initially immunized the most vulnerable, but broadened that to anyone over 45 on April 1 because of the surge in cases. The resulting increased demand forced the halt in exports. Since then, several top state officials have urged the federal government to further expand vaccinations.
Poonawalla said the company has “chosen to prioritize India temporarily for two months” and hopes to then restart exports.
If India’s surge in infections doesn’t subside, “I am scared of what ... we will have to do, and what will happen,” he said. “We are going to have to keep supplying to India, and not anywhere else. Because we have to protect our nation.”
He acknowledged that has put a “strain on our contractual obligations” to provide vaccines to other countries, and that he has been fielding phone calls from various heads of state.
“I’ve had to politely explain to everybody the situation,” he said, adding that most world leaders understood because they were facing the same issues — the needs of domestic politics and questions raised by opposition parties and the public.
“Nationalism is happening ... to a certain extent, everywhere,” Poonawalla said, pointing to vaccine export controls imposed by Europe, and the use in the United States of the Defense Production Act to prevent exports of critical raw materials needed to scale up vaccine manufacturing.
He said the unavailability of these raw materials, such as the specific medium needed to grow microorganisms, could affect the Serum Institute’s production of another vaccine, Novavax, which is still being tested in India.
It has signed a deal to supply Novavax to COVAX, but pivoting to different suppliers of the raw materials would result in a delay of five to six months, he said.
“The crunch ... for supplies is today,” he said.
Dr. Bruce Aylward, a senior adviser to World Health Organization Director-General Tedros Adhanom Ghebreyesus, said vaccine supplies for COVAX remain fluid.
“Obviously, if we have an interruption with any one of our suppliers for a short time, a month or so, we can find ways to try and manage as best we can with the countries. And if it’s longer than that, obviously it would be a big challenge,” he said at a WHO briefing on Tuesday.
“Clearly were there a complete interruption from any supplier, that would be a real problem,” he said.
India opens up immunization to more people, COVID-19 vaccine exports to dwindleIndia opened up its coronavirus inoculation program to people above 45 on Thursday as infections surge, which will delay vaccine exports from the ... Coronavirus
Asian countries seek COVID-19 vaccine supplies after India export curbs hit COVAXSeveral Asian countries sought alternative sources for COVID-19 inoculations on Tuesday after export restrictions by manufacturer India left a World ... Coronavirus
Biggest share of Indian-made vaccines under program for poor countries stays in IndiaIndia itself has received more than a third of the nearly 28 million Indian-made AstraZeneca COVID-19 vaccine doses delivered so far by the global ... Coronavirus
COVAX expects full vaccine supplies from India’s Serum in May, says UNICEFA World Health Organization (WHO)-backed program to supply coronavirus vaccines to poorer countries expects that the Serum Institute of India (SII) ... Coronavirus
India’s Serum Institute delays expected launch of Novavax COVID-19 vaccineThe launch in India of a new COVID-19 vaccine developed jointly by the Serum Institute of India and US-based biotech firm Novavax is likely to be ... Coronavirus
India tells overseas COVID-19 vaccine buyers it has to prioritize local needsIndia, the world’s biggest vaccine maker, said on Friday it would make domestic COVID-19 inoculations a priority as infections surge and had told ... Coronavirus
Alarm in Africa after India delays vaccines to COVAX program for poor countriesNews that India will delay deliveries of AstraZeneca’s COVID-19 vaccine to the global program to inoculating poor countries triggered alarm on ... Coronavirus